undamentalytics Newsletter
Sign in

Korro Bio, Inc. balance sheet

At the end of fiscal 2025, Korro Bio, Inc. had total assets of $114m, total liabilities of $62.1m and shareholders' equity of $51.4m. It held $21.8m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents2002208036166562225
Receivables————0210
Total current assets2212251355717313282121
Total assets22326518574222226114163
Accounts payable16337424
Deferred revenue (current)4814——0401
Total current liabilities532711919151213
Short-term debt——110————
Long-term debt0———————
Total debt0—1100000
Total liabilities567255952666260
Shareholders' equity167192−42−9917016051103
Non-controlling interests and other (assets − liabilities − equity)——173164————
Shares outstanding—————9m9m15m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CLGN vs KRROKRRO vs VTGNKRRO vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Korro Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Korro Bio, Inc.